Related stories
Samsung Biologics Says 97.98% Tendered in PolyPeptide Offer
Samsung Biologics is pursuing making PolyPeptide a wholly owned subsidiary after 97.98% of shares were tendered in its public offer.
M impact | MNA | Nov 02, 2026, 08:53 AM UTC
Blackstone-Led Group Agrees to $3.1 Billion LNG Canada Investment
A Blackstone-led investor group agreed to invest $3.1 billion in LNG Canada.
M impact | MNA | Nov 02, 2026, 08:32 AM UTC
Baker Hughes Closes $1.45 Billion Sale of Waygate Technologies
Baker Hughes completed the $1.45 billion sale of Waygate Technologies to Hexagon.
M impact | MNA | Nov 02, 2026, 08:31 AM UTC
Aspen verkauft europäische Ovestin-Rechte für 197 Millionen Euro an Ennogen
M impact | MNA | Nov 02, 2026, 08:30 AM UTC
Aspen Pharmacare Agrees to Sell European Ovestin Rights for EUR 197 Million
Aspen Pharmacare agreed to sell the European rights to Ovestin to Ennogen for EUR 197 million.
M impact | MNA | Nov 02, 2026, 08:30 AM UTC
Aspen Pharmacare to Sell European Ovestin Rights to Ennogen for EUR 197 Million
Aspen Pharmacare will sell the European rights to Ovestin to Ennogen for EUR 197 million, plus EUR 4 million in inventory.
M impact | MNA | Nov 02, 2026, 08:30 AM UTC